The therapeutic effect of second generation anti-androgens such as enzalutamide and abiraterone acetate implies most cancer cells, which still express functional AR, require AR signaling to evade traditional regulatory mechanisms to survive androgen deprivation strategies [7,8,47]. The gene discussed is AR; the disease is cancer.